We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+39.31%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$384M
AUM Growth
+$79.7M
Cap. Flow
-$19.4M
Cap. Flow %
-5.04%
Top 10 Hldgs %
83.76%
Holding
22
New
–
Increased
3
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
WVE icon
Wave Life Sciences
WVE
+$4.66M
2
XLRN
Acceleron Pharma
XLRN
+$837K
3
EPZM
Epizyme, Inc
EPZM
+$704

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$7.18M
2
IMMU
Immunomedics Inc
IMMU
+$4.78M
3
SLDB icon
Solid Biosciences
SLDB
+$2.65M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$2.17M
5
VRNA
Verona Pharma
VRNA
+$1.99M

Sector Composition

Rank Sector Weight
1 Healthcare 59.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$92.6M 24.12%
1,950,477
– –
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$46.2M 12.02%
2,403,398
-296,602
-11% -$4.78M
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$40.2M 10.45%
2,942,130
– –
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$37.4M 9.75%
467,682
– –
ASND icon
5
Ascendis Pharma A/S
ASND
$16.4B
$24M 6.25%
204,088
– –
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
$21.1M 5.49%
1,587,101
– –
RCUS icon
7
Arcus Biosciences
RCUS
$3.38B
$17.1M 4.44%
1,366,973
-661,903
-33% -$7.18M
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$16.3M 4.25%
314,400
-47,041
-13% -$2.17M
AIMT
9
DELISTED
Aimmune Therapeutics
AIMT
$14.5M 3.77%
647,254
-62,568
-9% -$1.47M
EPZM
10
DELISTED
Epizyme, Inc
EPZM
$12.4M 3.22%
998,278
+63
+0% +$704
BOLD
11
DELISTED
Audentes Therapeutics, Inc
BOLD
$12.3M 3.2%
315,331
– –
XLRN
12
DELISTED
Acceleron Pharma
XLRN
$11.9M 3.09%
254,923
+19,055
+8% +$837K
REPL icon
13
Replimune Group
REPL
$435M
$11.9M 3.09%
749,654
-30,002
-4% -$374K
WVE icon
14
Wave Life Sciences
WVE
$1.13B
$6.41M 1.67%
164,900
+114,900
+230% +$4.66M
FBRX icon
15
Forte Biosciences
FBRX
$1.57B
$6.17M 1.61%
1,515
-259
-15% -$1M
NTRA icon
16
Natera
NTRA
$36.3B
$5.2M 1.35%
252,255
– –
BHVN
17
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.93M 1.02%
76,379
-29,327
-28% -$1.27M
BDSI
18
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.34M 0.87%
629,656
– –
AKAO
19
DELISTED
Achaogen Inc
AKAO
$1.31M 0.34%
2,864,664
– –
ACRS icon
20
Aclaris Therapeutics
ACRS
$739M
– –
-265,694
Closed -$1.96M
SLDB icon
21
Solid Biosciences
SLDB
$775M
– –
-6,596
Closed -$2.65M
VRNA
22
DELISTED
Verona Pharma
VRNA
– –
-206,663
Closed -$1.99M

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q1 2019 Portfolio in Review

As of Q1 2019, Foresite Capital Management III held 22 positions worth $384M, up 26% from $304M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

Foresite Capital Management III withdrew a net $19.4M in Q1 2019, closing 3 positions and reducing 7 holdings. Its most notable exit was Solid Biosciences, an estimated $2.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 57% a quarter earlier.

Against the trend, Foresite Capital Management III added an estimated $4.66M to Wave Life Sciences.

  • Foresite Capital Management III added most to Wave Life Sciences in Q1 2019, an estimated $4.66M increase.
  • Foresite Capital Management III's biggest Q1 2019 reduction was Arcus Biosciences, cutting an estimated $7.18M.
  • Foresite Capital Management III fully exited Solid Biosciences in Q1 2019, selling an estimated $2.65M.
  • Foresite Capital Management III's ten largest holdings make up 84% of its $384M portfolio in Q1 2019.
  • Foresite Capital Management III opened 0 new positions and closed 3 in Q1 2019.
  • Foresite Capital Management III's portfolio value rose 26% quarter-over-quarter to $384M.

Based on Foresite Capital Management III's 13F filing for Q1 2019, filed 14 May 2019.